Treatment with anti-CD20, used in many diseases in which B cells play a pathogenic role, has been 26 associated with susceptibility to intracellular infections. Here, we studied the effect of anti-CD20 27 injection on CD8 + T cell immunity using an experimental model of Trypanosoma cruzi infection, in 28 which CD8 + T cells play a pivotal role. C57BL/6 mice were treated with anti-CD20 for B cell 29 depletion prior to T. cruzi infection. Infected anti-CD20-treated mice exhibited a CD8 + T cell 30 response with a conserved expansion phase followed by an early contraction, resulting in a strong 31 reduction in total and parasite-specific CD8 + T cells at 20 days postinfection. Anti-CD20 injection 32 decreased the number of effector and memory CD8 + T cells and reduced the frequency of 33 proliferating and cytokine producing CD8 + T cells. Accordingly, infected anti-CD20-treated mice 34 presented a lower cytotoxicity of T. cruzi peptide-pulsed target cells in vivo. All of these alterations 35 in CD8 + T cell immunity were associated with increased tissue parasitism. Anti-CD20 injection also 36 dampened an established CD8 + T cell response, indicating that B cells were involved in the 37 maintenance rather than the induction of CD8 + T cell immunity. Anti-CD20 injection also resulted in 38 a marked reduction in the frequency of IL-6-and IL-17A-producing cells, and only rIL-17A injection 39 partially restored the CD8 + T cell response in infected anti-CD20-treated mice. Thus, anti-CD20 40 reduced CD8 + T cell immunity, and IL-17A is a candidate for rescuing deficient responses either 41 directly or indirectly. 42
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Importance 44
Monoclonal antibody targeting the CD20 antigen on B cells is used to treat the majority of Non-45
Introduction 55
56
The anti-CD20 monoclonal antibody (mAb) has revolutionized the treatment of B-cell malignancies. 57
This antibody, which depletes B cells, has been a success for the treatment of non-Hodgkin's 58 lymphoma (1), chronic lymphocytic leukemia (2) and autoimmune disorders (3) and has also 59 provided information about the antibody-independent role of B cells (4, 5) . 60 B cells are known to produce antibodies (Abs), but they also take up, process and present soluble 61 antigens (Ags) and secrete cytokines. B cells were shown to produce IL-10 and to have regulatory 62 functions in autoimmune models of colitis, experimental autoimmune encephalitis (EAE) and 63
arthritis (6) (7) (8) (19, 20) . Strategies that generate a productive specific CD8 + T cell 78 response will lead to increased host protection, a reduction in symptoms, and a decrease in disease 79 transmission (21, 22 
CD8
+ T cell effector function was determined in vitro by CD107a mobilization and cytokine 155 production, as previously reported (28). Briefly, cell suspensions were cultured for 5 h with medium, 156 5 µg/ml TSKB20 (ANYKFTLV) peptide (Genscript Inc.) or 50 ng/mL PMA plus 500 ng/ml 157 ionomycin (Sigma) in the presence of monensin (Thermo Fisher Scientific) and a PE-labeled anti-158 CD107a mAb (Thermo Fisher Scientific, eBio1D4B). After culture, the cells were stained with a 159
PECy7-labeled anti-CD8 mAb, fixed and permeabilized with BD Cytofix/Cytoperm and Perm/Wash 160 (BD Biosciences) according to the manufacturer's instructions. After permeabilization, the cells were 161 incubated for 30 min at RT with the following anti-mouse Abs (Thermo Fisher Scientific): APC-162 labeled anti-IFNγ (XMG1.2) and PerCp-Cy5.5-labeled anti-TNF (MP6-XT22). 163
164
In vivo cytotoxicity assay 165
Spleen mononuclear cell suspensions from μ MT mice were pulsed for 1 h with 1 µg/ml of the 166 Tskb20, Tskb18 or PA8 (VNHRFTLV) peptides (target cells). In this setting, μ MT mice, which lack 167 mature B cells, were used to avoid circulating anti-CD20 killing of the transferred cells. . 
181
In vivo Anti-CD20-treated mice were administered with recombinant IL-6 or IL-17 taking into account their 183 production kinetics (Fig. 5A) and was followed by the contraction phase of the response (Fig. 1A, control mice) . injection, 8 days prior to the infection, significantly decreased splenic B cell numbers (Fig. S1 A-C) , 197 which persisted at very low levels until 20 dpi (Fig. S1B ) and influenced CD8 + T cells (Fig. 1A-C) . 198
Anti-CD20 injection resulted in a significantly reduced CD8 + T cell frequency and number at 20 dpi 199 (Fig. 1A, αCD20) . As expected from the depletion of B cells, normal uninfected anti-CD20-treated 200 mice had a higher frequency of CD8 + T cells compared to uninfected isotype-treated control mice 201 (Fig. 1A, day 0) . The frequency and number of splenic Tskb20-specific CD8 + T cells (parasite 202 specific CD8 + T cells) detected in infected control mice were similar to those of infected anti-CD20-203 treated mice until 14 dpi (Fig. 1B) . After that, the percentage dropped dramatically in anti-CD20-204 treated mice, which presented a significantly lower frequency and number of T. cruzi-specific CD8 + 205 T cells at 20 dpi, remaining low up to 35 dpi (the last day of our analysis) (Fig. 1B) . The frequency 206 and number of Tskb20-specific CD8 + T cells was also reduced in liver, a T. cruzi infection target 207 organ, of infected anti-CD20-treated mice at 20 dpi (Fig. 1C) . In concordance with the low number 208 of total and parasite-specific CD8 + T cells, anti-CD20-treated mice infected with T. cruzi had a 209 higher parasite load than controls, as evidenced by the T. cruzi DNA fold increase in the liver, spleen 210 and heart at 20 dpi (Fig. 1D) Fig. 2A) . When the values were 218 expressed in absolute numbers, we determined that anti-CD20-treated mice exhibited a significant 219 reduction in all CD8 + T cell subpopulations ( Fig. 2A) . The anti-CD20 injection decreased the 220 frequency and number of splenic Tskb20/Kb + CD8 + T cells with an effector phenotype but not the 221 number of Tskb20/Kb + CD8 + T cells with a naïve or central memory phenotype (Fig. 2B) . Next, we evaluated in vivo the cytotoxic capacity elicited in infected anti-CD20-treated mice in 259 comparison to that in infected control and uninfected mice. For the evaluation, differentially stained 260 antigen-parasite-loaded cells were transferred to the different groups of mice. Fig. 3C shows no 261 specific lysis of PA8-loaded cells since this peptide is mainly present in other strains of the parasite, 262 which are different from the strain used in this study (32) . In addition, in infected anti-CD20-treated 263 mice, the frequency of CFSE hi eFluor670 neg Tskb20-pulsed cells and CFSE neg eFluor670 + Tskb18-264 pulsed cells was higher than that in infected controls. The results indicate that infected anti-CD20-265 treated mice displayed a reduced capacity to specifically kill target cells pulsed with the parasite 266 antigens Tskb20 and Tskb18. 267 268
Anti-CD20 treatment affected an established CD8 + T cell response 269
To analyze whether anti-CD20 injection affected an already established CD8 + T cell response, T. 270 cruzi-infected mice were injected with anti-CD20 mAb at 12 dpi when the parasite-specific CD8 + T 271 cell frequency had nearly peaked (see Fig. 1B ). We determined that the injection of anti-CD20 at day 272 12 dpi induced a reduction in the frequency and number of splenic parasite-specific CD8 + T cells 273 after 20 dpi, which was comparable with the effect of the treatment initiated before infection (Fig.  274   4A) . When compared to infected control mice, mice treated with anti-CD20 after 12 dpi exhibited a 275 significantly reduced number of CD8 + T cells with SLEC and MPEC phenotypes (Fig. 4B ) and a 276 diminished frequency of IFNγ + CD8 + T cells in splenocytes evaluated after polyclonal or antigen-277 specific stimulation (Fig. 4C ). In line with the reduced frequency of IFNγ + -producing cells, total and 278 parasite-specific CD8 + T cells from infected mice treated with anti-CD20 mAb at 12 dpi expressed 279 lower levels of Tbet than CD8 + T cells from infected control mice (Fig. 4D ). In our experimental 280 model, the results indicated that anti-CD20 injection did not affect the induction of the CD8 + T cell 281 response (see Fig. 1A ) but probably affected their survival/maintenance. 282
B cells from T. cruzi-infected mice produce cytokines involved in CD8 + T cell survival 284
Cytokines contribute to the regulation of the contraction of the response, as well as the long-term 285 maintenance of memory CD8 + T cells (28, (33) (34) (35) . Based on this and considering that anti-CD20 286 injection depletes B cells from mice, we hypothesize that B cells could be the source of cytokines 287 involved in the maintenance of the CD8 + T cell response. By flow cytometry, we observed that T. 288 cruzi-infected mice had IL-6 and IL-17A-producing B cells, and the numbers of these cells peak at 289 15 dpi and remained high at 20-30 dpi (Fig. 5A) . In comparison to lymphoid non-B cells, B cells 290 were the main source of IL-6 and IL-17A (Fig. 5A) , while the main source of IL-10, IFNγ and TNF 291 within the lymphoid population were non-B cells (Fig. S4) . 292
When mice were treated with anti-CD20 mAb prior to infection, a significant decrease in IL-6-and 293 IL-17A-producing lymphoid cells was observed (Fig. 5B) . Most of the cytokine-producing B cells 294 were CD19 low , which is compatible with the plasmablast phenotype (11). Interestingly, anti-CD20 295 injection before the infection did not affect serum IL-6 concentration since IL-6 values were similar 296 either at 15 and 20 dpi (Fig. 5C ). The IL-17A concentration was undetectable in the sera from both 297 groups of infected mice (data not shown). 298
Next, by immunofluorescence, we evaluated the spatial distribution of splenic B-, CD8
+ T-and IL-299 17A-producing cells. Fig. 5D shows B cell follicles (B220 To evaluate the hypothesis that the absence/diminution of IL-17A could affect the maintenance of 312 the CD8 + T cell response in infected anti-CD20-treated mice, groups of these mice were injected with 313 rIL-17A or PBS. Fig. 6 shows that injections of rIL-17A partially increased the frequency and 314 number of total and Tskb20-specific CD8 + T cells (Fig. 6A) . In particular, the frequency and number 315 of total and Tskb20-specific SLEC CD8 + T cells, but not the frequency and number of the MPEC 316
CD8
+ T cell population, were increased by rIL-17A supplementation (Fig. 6B) . 317
In addition, rIL-17A partially increased the frequency and number of IFNγ-producing CD8 + T cells 318 and restored the frequency of TNF-producing CD8 + T cells (Fig. 7A) . The increase in the frequency 319 of IFNγ-producing CD8 + T cells in infected anti-CD20-treated mice injected with rIL-17A was 320 accompanied by an increase in Tbet expression in total and Tskb20-specific CD8 + T cells (Fig. 7B) . 321
As expected, the increase in the number and functionality of CD8 + T cells in infected anti-CD20-322 treated mice injected with rIL-17A was associated with a strong reduction in the parasite load in the 323 liver, spleen and heart (Fig. 7C) . 324
Recombinant IL-6 injection in infected anti-CD20 treated mice did not increase the frequency and 325 number of total and Tskb20-specific CD8 + T cells (Fig. 8A ) and did not modify the frequency and 326 number of SLECs and MPECs CD8 + T cell subsets (Fig. 8B) . In addition, IL-6 injection to infected 327 anti-CD20 treated mice was not able to modify total and Tskb20-specific INFγ-producing CD8 + T 328 cells (Fig. 8C) , nor Tbet expression in CD8 + T cells (Fig. 8D) . 329
Discussion 330 An understanding of the effects of anti-CD20 treatment, which leads to the elimination of B cells, on 331 other cell types allows the identification of different side effects of this therapy and highlights the 332 Ab-independent functions of B cells. In this study, we show that anti-CD20 injection altered 333 antiparasitic CD8 + T cell immunity when administered prior to the infection or after when the 334 specific CD8 + T cell response was already established. In our work, we determined that the CD8 + T 335 cell decrease in infected anti-CD20-treated mice affected both effector and memory cell numbers. proportion of the HIV-specific T cell response with the highest functionality inversely correlated 362 with the viral load in progressors (39). Accordingly, the deficient polyfunctionality of CD8 + T cells 363 from infected anti-CD20-treated mice was associated with a higher parasite load at 20 dpi. Notably, 364 it has been reported that patients treated with anti-CD20 can develop different viral infections, which 365 are the most common non-hematological adverse effects of this therapy. Viral infections in patients 366 receiving anti-CD20 include severe respiratory tract infections, hepatitis B virus reactivation and 367 varicella-zoster virus infection (40-42). Based on our results, we hypothesize that treatment of 368 patients with anti-CD20 not only affects Ab-secreting cells, which can neutralize viruses, but could 369 also affect the development or establishment of CD8 + T cell responses, which are necessary for the 370 control of intracellular infections. Additionally, we also observed that anti-CD20 did not modify 371 
cells (45). 395
Considering that the transfer of purified antibodies was not performed in that study, it is possible that 396 the observed effect may be associated with the presence of IL-17A in addition to the specific 397 antibodies. 398
High microorganism load, together with persistent antigenic stimulation, are considered the most 399 important factors influencing CD8 + T cell exhaustion and consequent loss of functionality. In T. 400 cruzi infection, the relationship between parasite load and CD8 + T cell dysfunction is controversial. 401
We (28) 
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The authors declare no competing interests. 448 homeostasis and expansion during acute viral infection in mice. independent experiments. 648 649 FIGURE 4. T. cruzi infected mice treated with anti-CD20 mAb at 12 dpi also had a reduced 651 CD8 + T cell response.
652
Mice infected with 5000 trypomastigotes of T. cruzi Tulahuén strain were injected with isotype 653 control (control; white bars) or anti-CD20 mAb at 12 dpi (12dpi α CD20; gray bars). Mice injected 654 with anti-CD20 mAb 8 days before the infection with 5000 trypomastigotes of T. cruzi Tulahuén 655 strain were processed in parallel (αCD20; black bars). satellite DNA in liver, spleen and heart determined at 20 dpi. Murine GAPDH was used for 707 normalization. N= 5-6 (A-B) and 3-4 (C) mice per group. P values were calculated with one-way 708 ANOVA followed by Bonferroni's posttest. Data are representative of three (A-B) and two (C) 709 independent experiments. 710 711 FIGURE 8. IL-6 did not modify the magnitude and effector phenotype of the CD8 + T cell 712 response observed in infected anti-CD20-treated mice 713
Mice infected with 5000 trypomastigotes of T. cruzi Tulahuén strain were injected with isotype 714 control (control; white bars) or anti-CD20 mAb 8 days before infection. Infected mice injected with 715
anti-CD20 mAb were also injected with PBS (αCD20, black bars) or rIL-6 (αCD20 + rIL-6, gray 716 bars) at 12, 14, 16 and 18 dpi. The spleens of the different groups of mice were obtained at 20 dpi. 
